AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02885012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: At entry to the study following the screen visits, patients will be switched from bosentan to ambrisentan to complete a 24 week trial. The only study intervention will be ambrisentan.
Study NCT02206048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proflavine
Description: 0.01% proflavine solution topically applied to cervix before high-resolution microendoscopy (HRME) imaging.
Study NCT02206048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-Resolution Microendoscopy (HRME) Imaging
Description: in-vivo high-resolution microendoscopy (HRME) images of cervical adenocarcinoma in situ (AIS) performed immediately prior to conization.
Study NCT04412408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab is administered every 21 days until the disease progresses or treatment is terminated due to unacceptable toxicity. For patients with clinical and radiologic benefits, treatment can last up to 2 years.~Dose: 2 mg / kg intravenously for 60 min (± 10 min window)
Study NCT00075010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 15 mg/m\^2 by vein over 1 hour times 10 days
Study NCT00075010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic acid
Description: 20 mg/kg given orally daily for 10 days
Study NCT04943315 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Monolithic zirconia
Description: posterior crowns
Study NCT04943315 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Metal-ceramic
Description: posterior crowns
Study NCT00595530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: Medication administered via IV. This study will utilize 4 doses of ketamine: 0.05 mg/kg/hr, 0.1 mg/kg/hr, 0.15 mg/kg/hr, and 0.2 mg/kg/hr.~Dosing Regimen:~* Patients begin the ketamine infusion at 0.05 mg/kg/hr.~* 4 or more hrs after infusion is started, the dose may be increased to 0.1 mg/kg/hr if:~  1. patient's pain has not improved to an acceptable level~ 2. side effects remain acceptable~* 4 hrs or more after the previous increase, the dose may be adjusted to 0.15 mg/kg/hr~* 4 hrs or more after the previous increase, the dose may be adjusted to 0.2 mg/kg/hour~* Maximum dose of ketamine is limited to 300 mg per 24 hrs~Patient may receive ketamine up to 72 hrs after initiation.
Study NCT01565512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: A total of 100 mg bupivacaine (20 mL of 5 mg/mL solution) administered once by subcutaneous injection while patient is under general anesthesia at end of operation.
Study NCT01565512 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: A total of 20 mL on injectable saline(0.9% NS) administered once by subcutaneous injection while patient is under general anesthesia at end of operation.
Study NCT01260636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobenate Dimeglumine
Description: 0.1 mmol/kg, single dose
Study NCT01260636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gadopentetate Dimeglumine
Description: Double dose of 0.2 mmol/kg
Study NCT02495298 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascial Manipulation
Description: The Fascial Manipulation was performed by a physiotherapist on the spots indicated by clinician as the most painful ones due to CTS. The selected spots were informed to the physiotherapist after the clinical anamnesis.
Study NCT02495298 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Fascial Manipulation
Description: After the clinical anamnesis, a physiotherapist performed the Fascial Manipulation on different spots, rather than the spots the clinician considered the most painful ones due to CTS.
Study NCT01235351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75 mg daily, 150 mg daily, 225 mg daily, and 300 mg daily based on genotype
Study NCT01235351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75 mg daily, 150 mg daily
Study NCT03600545 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain Fitness App
Description: Brain exercises using an iPAD
Study NCT02079220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm A
Description: * Capecitabine~* Oxaliplatin~* Ziv-aflibercept
Study NCT02079220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm B
Description: Capecitabine Oxaliplatin Ziv-aflibercept
Study NCT03394326 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: family-based obesity prevention lifestyle intervention
Description: A family-based obesity prevention lifestyle intervention is based on the combination of behavioral therapy strategies, a physical activity prescription and a dietary prescription. Both the parent and child will be working to achieve the same behavioral targets.
Study NCT02951728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT03394326 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: family-based obesity prevention lifestyle intervention
Description: A family-based obesity prevention lifestyle intervention is based on the combination of behavioral therapy strategies, a physical activity prescription and a dietary prescription. Both the parent and child will be working to achieve the same behavioral targets.
Study NCT01340885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Strattera
Description: 10-30 mg b.i.d. for 6 weeks
Study NCT01340885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exelon
Description: 1.5-4.5 mg b.i.d. for 6 weeks
Study NCT01340885 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2-6 pills for 6 weeks
Study NCT04256798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash
Description: 0.2% Chlorhexidine digluconate
Study NCT04256798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Oxygen 80-100%
Study NCT04256798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Oxygen 80-100%
Study NCT04256798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Oxygen 21-30 %
Study NCT04256798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Oxygen 21-30 %
Study NCT02505997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Single 5 mg oral dose of midazolam syrup given in the AM on Day 1 and Day 8.
Study NCT02505997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delafloxacin
Description: Oral 450 mg delafloxacin tablets given twice daily (Q12h) on Days 3 to 8
Study NCT03748797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise training under supervision
Description: Upper and lower limbs cycling, treadmill walking, multi-gym strengthening, stepper exercise, dumb bell and squatting exercise
Study NCT00940225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Study NCT00940225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04388618 — intervention group
Intervention type: OTHER
Intervention: NHANES smell and taste tests
Description: participants will be asked to smell 8 cards of different odors and submit your choices in a given card, and so for 3 different taste tips (salty, bitter and neutral). participants will be asked to submit his choices in a given card as well. Then participants photograph those cards and send it via WhatsApp to a given number to be collected
Study NCT04249583 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin
Description: neuromodulator to be injected in the GL region
Study NCT04249583 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to be injected in the GL area
Study NCT01004627 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arterial and venous duplex ultrasound examination
Description: Ultrasound mapping of all blood vessels in the upper limb of interest
Study NCT03636932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine (NAC)
Description: Intravenous injection of 2 gram of N-acetylcysteine (NAC) during 4 weeks, 3 times per week during the first three hours of dialysis.
Study NCT03636932 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous injection of 2 gram of Placebo during 4 weeks, 3 times per week during the first three hours of dialysis.
Study NCT03636932 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: Circulating tissue factor assay
Study NCT03636932 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Blood sample
Description: Circulating tissue factor assay
Study NCT03636932 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: The test of pro-coagulant activity of the tissue factor
Study NCT03636932 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Blood sample
Description: The test of pro-coagulant activity of the tissue factor
Study NCT02835924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Study NCT02835924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Study NCT01661296 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RFH therapy
Description: RFH therapy was administered by a single, controlled and localized delivery of radio frequencies into the lesion for 30-60 seconds under local anesthesia using a current field radio-frequency generator.
Study NCT01661296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium stibogluconate
Description: Six intralesional injections (one injection per week) of SSG 50mg/cm-2 area of lesions
Study NCT04070274 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: different types of surgery platforms
Description: 58 patients with lateral calcaneus surgeries are divided into the control group of 29 patients and the experimental group with 29 patients. The traditional lateral method and calcaneus lateral surgery platforms are separately applied in the groups.
Study NCT01504035 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthostat-L
Description: Application of nx2g Lidocaine loaded hemostatic putty, i.e. Orthostat-L at the iliac crest bone graft harvest site
Study NCT01504035 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthostat
Description: Application of nx2g hemostatic putty, i.e. Orthostat at the iliac crest bone graft harvest site
Study NCT05604118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 1 week of aspirin supplementation prior to sampling
Study NCT02824874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvie Tab. 0.5mg
Description: Duvie Tab. 0.5mg\*1T/day for 5days, QD, PO
Study NCT02824874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvie Tab. 0.5mg + Januvia Tab. 100mg
Description: Duvie Tab. 0.5mg + Januvia Tab.100mg\*1T/day for 5 dyas, QD, PO
Study NCT00806390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Metroprolol tartrate titrated up
Study NCT01925300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concor 5mg 2T and Crestor 20 mg 1Tab
Study NCT02242032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P-321 Ophthalmic Solution
Study NCT02242032 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: P-321 Ophthalmic Solution placebo
Description: Placebo to match P-321 Ophthalmic Solution
Study NCT02951728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Study NCT02951728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Study NCT02951728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study NCT02951728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Study NCT02689089 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 3HP
Description: An interrupted time series study design will be used to determine if the introduction of the 3HP regimen will result in more people completing LTBI treatment compared to the standard of 9 months INH twice weekly.
Study NCT01023516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9668
Description: 2 x 30 mg oral tablets bd for 12 weeks
Study NCT03972046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib (MEK Inhibitor)
Description: Trametinib (MEK Inhibitor) 2 mg by mouth once a day
Study NCT01023516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 x matched placebo to oral tablet bd for 12 weeks
Study NCT02023541 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Proton beam therapy
Study NCT03529175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abraxane (nab-paclitaxel)
Study NCT03529175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Study NCT01282892 — intervention group
Intervention type: PROCEDURE
Intervention: excess of visceral fat
Description: excess of visceral fat
Study NCT01282892 — intervention group
Intervention type: PROCEDURE
Intervention: patients with NAFLD
Description: patients with NAFLD
Study NCT03647397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photo Electrochemical Oxidation (PECO) for Air Purification
Description: PECO air purifiers from Molekule will be placed in every patient room. Health metrics will be tracked for patients whose diagnosis is respiratory distress.
Study NCT02950532 — intervention group
Intervention type: OTHER
Intervention: Retrospective radiological evaluation
Description: Radiological evaluation will be performed in already existing imaging exams. Superior-inferior end plate angle (SIEA), vertebral body height (BH), local kyphosis (LK), inter-spinous distance (ISD) and inter-pedicular distance (IPD) will be measured in CT scans and radiographs (if available). PLC injury will be determinated with the gold standard method (MRI).
Study NCT02980601 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Integra plus STSG
Description: A sheet of Integra directly on the wound bed with subsequent removal of the overlying silicone sheet and immediate application of a 0.008mm STSG
Study NCT01822249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPI-743
Study NCT01822249 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03746938 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VB-C01
Description: Surgical implant of VB-C01 (Collagen membrane seeded with allogeneic stem cells isolated from adipose tissue, ADSC).
Study NCT01917591 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Punch biopsies treated with MariGen Wound ECM dressing
Description: Weekly dressing changes and review of wounds.
Study NCT01917591 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Punch biopsies treated with Oasis ECM dressing
Description: Weekly dressing changes and wound review
Study NCT03814460 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of Tone, Pain and Thickness
Description: Evaluation of Muscle state of tension, self-reported response to mechanical pressure pain and muscle thickness. The evaluation process of muscle tone and pressure pain sensitivity will be carried out following a topographical mapping covering myotendinous and muscle belly sites in the biceps brachii and the gastrocnemius muscles
Study NCT00269620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol/etonogestrel vaginal ring
Description: vaginal ring for cyclic use (3 weeks in, 1 week out)
Study NCT00269620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol/norelgestromin transdermal contraceptive
Description: contraceptive patch worn for 7 days and replaced for use for 3 consecutive weeks followed by a one-week patch free interval
Study NCT02820480 — intervention group
Intervention type: DEVICE
Intervention: Rehab in a Crate System
Description: The therapy gym is Rehab in a Crate with 4 stations for upper and lower limb assessment/therapy. Each station will allow adaptive game-based therapy.~Note: The device is not being used at this moment for diagnostic or evaluation. Users will be asked to explore the device, try the systems, and provide feedback about use.
Study NCT03456414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality exercise during hemodialysis
Description: Subjects will play a virtual reality game specially adapted for subjects undertaking hemodialysis treatment
Study NCT05233423 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: compressed cold therapy bandage
Description: Compressed cold therapy bandage was applied by wrapping the operated knee of the patients. The patients in the intervention group received 9 cold applications with 30 mmHg pressure for 20 minutes and 40 minutes of rest.
Study NCT02980601 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: STSG
Description: 0.012mm STSG
Study NCT02980601 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: STSG
Description: 0.012mm STSG
Study NCT03475537 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: the treatment of transcranial direct current stimulation
Study NCT02747095 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IQon Spectral CT
Description: Using IQon Spectral CT, Assess the added diagnostic value and impact on workflow of spectral images
Study NCT04812964 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein powder supplement, standard dosage based on 0.5 gram protein per pound of subject's lean body mass
Description: Standard protein diet as control, based on 0.5 gram protein per pound of lean body mass, isocaloric (same number of calories) and consisting of 15% protein and 55% carbohydrate.
Study NCT04812964 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein powder supplement, High Level Protein, based on 1 gram of protein per pound of lean body mass: 25% protein and 45% carbohydrate
Description: High level of protein diet, based on 1 gram of protein per pound of subject's lean body mass, isocaloric (same number of calories) and consisting of 30% protein and 40% carbohydrate.
Study NCT01801891 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VASGARD stimulator
Description: The VASGARD device is a 2 channel muscle stimulator system designed for increasing venous blood flow. Controlled electrical stimuli are delivered to the patient through adhesive gel electrodes placed over the motor points of muscles on the lower leg. This elicits artificial muscular contractions which in turn increases lower limb venous haemodynamics.
Study NCT01801891 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression bandaging
Description: Compression bandaging systems apply graduated external pressure to the lower limb to promote venous return to the heart reducing venous hypertension and thereby facilitate venous ulcer healing.
Study NCT01801891 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression bandaging
Description: Compression bandaging systems apply graduated external pressure to the lower limb to promote venous return to the heart reducing venous hypertension and thereby facilitate venous ulcer healing.
Study NCT00594438 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synthes Reamer-Irrigator-Aspirator (RIA)
Description: A standard lateral approach to the proximal femur will be utilized. The starting point will be identified using a guide pin and fluoroscopy using standard technique. The attending surgeon will perform the case from the opening of the canal with a drill through the completion of reaming. A transesophageal echocardiogram (TEE) will be recorded from the time the initial reamer engages the cortex until it is removed from the bone. A guide wire will be passed across the fracture site and its position confirmed by fluoroscopic imaging. The femoral canal will be reamed using the RIA device.
Study NCT00594438 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zimmer Sentinel Reamer
Description: A standard lateral approach to the proximal femur will be utilized. The starting point will be identified using a guide pin and fluoroscopy using standard technique. The attending surgeon will perform the case from the opening of the canal with a drill through the completion of reaming. A transesophageal echocardiogram TEE will be recorded from the time the initial reamer engages the cortex until it is removed from the bone. A guide wire will be passed across the fracture site and its position confirmed by fluoroscopic imaging. The femoral canal will be reamed using either a conventional reaming technique or the RIA device.
Study NCT03846596 — intervention group
Intervention type: BIOLOGICAL
Intervention: Additional blood tube
Description: Additional blood tube during care
Study NCT02185833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DIRITHROMYCIN 500 MG ENTERIC COATED TABLET
Study NCT02185833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DYNABAC 250 MG ENTERIC COATED TABLET
Study NCT02259868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS /1B, current low dose formulation